Your session is about to expire
← Back to Search
Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics (DREAM-ON Trial)
N/A
Recruiting
Led By Richard E Pratley, MD
Research Sponsored by Milton S. Hershey Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the frequently sampled intravenous glucose tolerance test (fsigtt) administered at 3 and 12 months
Awards & highlights
No Placebo-Only Group
Summary
The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.
Eligible Conditions
- Pancreatitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during the oral glucose tolerance test (ogtt) administered at 3, 12, 24, and 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the oral glucose tolerance test (ogtt) administered at 3, 12, 24, and 36 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
diabetes mellitus following an episode of acute pancreatitis
pre-diabetes mellitus following an episode of acute pancreatitis
Secondary study objectives
acute insulin response to glucose
fasting glucose
initiation of insulin therapy
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CGMExperimental Treatment1 Intervention
Continuous Glucose Monitoring (CGM)
Find a Location
Who is running the clinical trial?
Milton S. Hershey Medical CenterLead Sponsor
510 Previous Clinical Trials
2,795,660 Total Patients Enrolled
2 Trials studying Pancreatitis
1,306 Patients Enrolled for Pancreatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,456 Previous Clinical Trials
4,334,331 Total Patients Enrolled
27 Trials studying Pancreatitis
32,811 Patients Enrolled for Pancreatitis
Benaroya Research InstituteOTHER
49 Previous Clinical Trials
11,457 Total Patients Enrolled
2 Trials studying Pancreatitis
998 Patients Enrolled for Pancreatitis
Cedars-Sinai Medical CenterOTHER
512 Previous Clinical Trials
162,564 Total Patients Enrolled
11 Trials studying Pancreatitis
1,520 Patients Enrolled for Pancreatitis
University of Southern CaliforniaOTHER
946 Previous Clinical Trials
1,604,023 Total Patients Enrolled
11 Trials studying Pancreatitis
4,172 Patients Enrolled for Pancreatitis
Indiana UniversityOTHER
1,040 Previous Clinical Trials
1,219,264 Total Patients Enrolled
12 Trials studying Pancreatitis
3,256 Patients Enrolled for Pancreatitis
Johns Hopkins UniversityOTHER
2,332 Previous Clinical Trials
14,873,950 Total Patients Enrolled
9 Trials studying Pancreatitis
8,055 Patients Enrolled for Pancreatitis
Ohio State UniversityOTHER
871 Previous Clinical Trials
654,662 Total Patients Enrolled
12 Trials studying Pancreatitis
2,810 Patients Enrolled for Pancreatitis
Stanford UniversityOTHER
2,484 Previous Clinical Trials
17,515,294 Total Patients Enrolled
7 Trials studying Pancreatitis
1,053 Patients Enrolled for Pancreatitis
University of FloridaOTHER
1,404 Previous Clinical Trials
765,530 Total Patients Enrolled
4 Trials studying Pancreatitis
877 Patients Enrolled for Pancreatitis